



V03
5-10-02

TECH CENTER 1500/2900

RECEIVED
PATENT
MAY 03 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Gehlsen, K.R.) Group Art Unit: 616
App. No. : 10/068,447)
Filed : February 6, 2002)
For : METHODS AND COMPOSITIONS)
FOR TOPICAL TREATMENT OF)
DAMAGED TISSUE USING)
REACTIVE OXYGEN METABOLITE)
PRODUCTION OR RELEASE)
INHIBITORS)
Examiner : Unknown)

INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

Enclosed is form PTO-1449 listing references that are also enclosed. This Information Disclosure Statement is being filed within three months of the filing date of this application or upon filing if this is a CPA or RCE, and no fee is required in accordance with 37 C.F.R. § 1.97(b)(1), (b)(2), or (b)(4).

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: April 26, 2002

By: AnneMarie Kaiser
AnneMarie Kaiser
Registration No. 37,649
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(619) 235-8550

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. MAXIM.073DV1C1	APPLICATION NO. 10/068,447	RECEIVED MAY 03 2002 TECH CENTER 1600/2900
	APPLICANT Kurt R. Gehlsen		
	FILING DATE February 6, 2002	GROUP 1616	

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS									
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
							YES	NO	

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
1	Freeman, G.R. (1976) DMSO in otology. Laryngoscope. 86:921-929.	
2	Fulton et al. (1959) The mechanism of action of rubefacients. The Journal of Investigative Dermatology. 33:317-325.	
3	Goodson et al. (1976) Augmentation of some aspects of wound healing by a "skin respiratory factor" Journal of Surgical Research. 21:125-129.	
4	Hummon, Jr., I.F. (1944) Histamine ion transfer, a five year evaluation. Archives of Physical Therapy. 25:212-216.	
5	Kling, D.H. (1934) Histamine therapy of rheumatic affections and disturbances of the peripheral circulation. Annals of Surgery. 99:568-576.	
6	Osol et al. (1955) Histamine Phosphate injection. The Dispensary of the United States of America. 25 th Ed., J.B. Lippincott Company. p.649.	
7	Osol et al. (1973) Histamine phosphate. The United States Dispensary. 27 th Ed., J.B. Lippincott Company. 583-585.	
8	Osol et al. (1975) Histamine phosphate USP. Remington's Pharmaceutical Sciences. 15 th Ed., Mack Publishing Company. p.1056.	
9	Selle, W.A. (1946) Histamine-Its physiological, pharmacological and clinical significance. Texas Reports on Biology and Medicine. 4(1):138-244.	
10	Shelley et al. (1949) Factors accelerating the penetration of histamine through normal intact human skin. The Journal of Investigative Dermatology. 13:61-71.	
11	Sollmann, T. (1957) Histamine. A Manual of Pharmacology and its Applications to Therapeutics and Toxicology. 8 th Ed., W.B. Saunders Company. 538-540.	

S:\DOCS\MKD\MKD-2725.DOC\042502

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	